| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $20,246 | 1 | 33 |
Sells | $6,516 | 2 | 67 |
| Mor George Adi | Chief Executive Officer | 1 | $20,246 | 0 | $0 | $20,246 |
| Cohen Neil Harris | director | 0 | $0 | 2 | $6,516 | $-6,516 |
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano …
Over the last 12 months, insiders at Chemomab Therapeutics Ltd. have bought $20,246 and sold $6,516 worth of Chemomab Therapeutics Ltd. stock.
On average, over the past 5 years, insiders at Chemomab Therapeutics Ltd. have bought $33,141 and sold $1.25M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Mor George Adi (Chief Executive Officer) — $20,246.
The last purchase of 9,804 shares for transaction amount of $20,246 was made by Mor George Adi (Chief Executive Officer) on 2026‑05‑29.
| 2026-08-28 | Sale | Cohen Neil Harris | director | 1,000 0.0129% | $2.80 | $2,800 | -48.16% | |
| 2026-08-27 | Sale | Cohen Neil Harris | director | 1,304 0.0171% | $2.85 | $3,716 | -48.16% | |
| 2026-05-29 | Mor George Adi | Chief Executive Officer | 9,804 0.1645% | $2.07 | $20,246 | -17.50% | ||
| 2023-01-03 | Sale | OrbiMed Israel GP Ltd. | director | 336,900 3.61% | $3.58 | $1.21M | -53.74% | |
| 2023-01-03 | Sale | Mor George Adi | Chief Scientific Officer | 13,800 0.2073% | $5.03 | $69,370 | -53.74% | |
| 2022-11-16 | Sale | Mor George Adi | Chief Scientific Officer | 582,023 4.6768% | $2.08 | $1.21M | -32.46% | |
| 2022-11-16 | Sale | Cohen Neil Harris | director | 2,409 0.0186% | $2.00 | $4,818 | -32.46% | |
| 2022-05-24 | Maryles Joel Michael | 33 0.0003% | $2.76 | $91 | -20.36% | |||
| 2022-05-18 | Cohen Neil Harris | 2,000 0.0183% | $3.19 | $6,380 | -26.14% | |||
| 2022-03-18 | Maryles Joel Michael | 500 0.0043% | $4.36 | $2,180 | -37.28% | |||
| 2022-03-16 | Marvin Donald | Executive VP, CFO & COO | 250 0.0017% | $3.30 | $825 | -32.22% | ||
| 2022-03-14 | Cohen Neil Harris | 2,000 0.0186% | $4.20 | $8,400 | -27.20% | |||
| 2022-03-14 | Pfost Dale R | Chief Executive Officer | 1,800 0.0158% | $3.98 | $7,164 | -27.20% | ||
| 2022-03-14 | Marvin Donald | Executive VP, CFO & COO | 250 0.0022% | $4.00 | $1,000 | -27.20% | ||
| 2022-03-11 | Darvish Nissim | 1,200 0.0107% | $4.28 | $5,136 | -30.48% | |||
| 2021-12-06 | Cohen Neil Harris | director | 2,000 0.0175% | $7.43 | $14,860 | -54.24% | ||
| 2021-03-16 | THIEL PETER | 10 percent owner | 230,536 0.6772% | $17.35 | $4M | -83.55% | ||
| 2021-03-16 | Cohen Neil Harris | director | 2,409 0.0169% | $41.51 | $99,998 | -83.55% |
| Mor George Adi | Chief Executive Officer | 139131 1.9202% | $164,174.58 | 1 | 2 | |
| Cohen Neil Harris | director | 33000 0.4554% | $38,940.00 | 4 | 3 | <0.0001% |
| THIEL PETER | 10 percent owner | 1108509 15.2991% | $1.31M | 1 | 0 | <0.0001% |
| Pfost Dale R | Chief Executive Officer | 1800 0.0248% | $2,124.00 | 1 | 0 | <0.0001% |
| Marvin Donald | Executive VP, CFO & COO | 1750 0.0242% | $2,065.00 | 2 | 0 | <0.0001% |
| Maryles Joel Michael | 1433 0.0198% | $1,690.94 | 2 | 0 | <0.0001% | |
| Darvish Nissim | 1200 0.0166% | $1,416.00 | 1 | 0 | <0.0001% |
$76,600 | 22 | -38.58% | $10.49M | |
$812,698 | 12 | -57.09% | $7.89M | |
Chemomab Therapeutics Ltd. (CMMB) | $4,146,041 | 11 | -40.86% | $8.55M |
$120,379 | 10 | -24.48% | $7.65M | |
$4,176,565 | 9 | 18.77% | $9.3M |
| Increased Positions | 10 | +66.67% | 280,166 | +71.63% |
| Decreased Positions | 7 | -46.67% | 303,913 | -77.7% |
| New Positions | 6 | New | 265,439 | New |
| Sold Out Positions | 4 | Sold Out | 210,241 | Sold Out |
| Total Postitions | 18 | +20% | 367,379 | -6.07% |
| Sphera Funds Management Ltd. | $321.00 | 0.04% | 179,425 | -5,087 | -2.76% | 2025-09-30 |
| Morgan Stanley | $161.00 | 0.02% | 90,065 | -313,469 | -77.68% | 2025-09-30 |
| Ikarian Capital, Llc | $95.00 | 0.01% | 53,262 | <1 | <0.01% | 2025-09-30 |
| Stonepine Capital Management, Llc | $54.00 | 0.01% | 30,000 | +30,000 | New | 2025-09-30 |
| Jane Street Group, Llc | $39.00 | <0.01% | 21,511 | +16,369 | +318.34% | 2025-09-30 |
| Rhumbline Advisers | $17.00 | <0.01% | 9,505 | -464 | -4.65% | 2025-09-30 |
| Bnp Paribas Financial Markets | $10.00 | <0.01% | 5,750 | +2,275 | +65.47% | 2025-09-30 |
| Gamma Investing Llc | $1.00 | 0% | 667 | -2,536 | -79.18% | 2025-09-30 |
| Ubs Group Ag | $0 | 0% | 99 | 0 | 0% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0% | 26 | -2 | -7.14% | 2025-09-30 |